Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial
Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE–EGCG complex (85 mg NOPE...
Saved in:
| Published in | British journal of nutrition Vol. 101; no. 3; pp. 457 - 464 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cambridge, UK
Cambridge University Press
01.02.2009
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE–EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE–EGCG group and 27 % in the placebo group (P < 0·001). The treatment induced a significant weight reduction in both groups ( − 3·28 kg and − 2·67 kg in NOPE–EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE–EGCG treatment improved insulin resistance (P < 0·001), the sensation feelings of fullness (P < 0·05), depressive symptoms (P < 0·004) and severity of binge eating (P < 0·0001). |
|---|---|
| AbstractList | Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0·001). The treatment induced a significant weight reduction in both groups ( - 3·28 kg and - 2·67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0·001), the sensation feelings of fullness (P < 0·05), depressive symptoms (P < 0·004) and severity of binge eating (P < 0·0001). Many studies have found that N -oleyl-ethanolamine (NOE), a metabolite of N -oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE–EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE–EGCG group and 27 % in the placebo group ( P < 0·001). The treatment induced a significant weight reduction in both groups ( − 3·28 kg and − 2·67 kg in NOPE–EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE–EGCG treatment improved insulin resistance ( P < 0·001), the sensation feelings of fullness ( P < 0·05), depressive symptoms ( P < 0·004) and severity of binge eating ( P < 0·0001). Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0.001). The treatment induced a significant weight reduction in both groups ( - 3.28 kg and - 2.67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0.001), the sensation feelings of fullness (P < 0.05), depressive symptoms (P < 0.004) and severity of binge eating (P < 0.0001).Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0.001). The treatment induced a significant weight reduction in both groups ( - 3.28 kg and - 2.67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0.001), the sensation feelings of fullness (P < 0.05), depressive symptoms (P < 0.004) and severity of binge eating (P < 0.0001). Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE–EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE–EGCG group and 27 % in the placebo group (P < 0·001). The treatment induced a significant weight reduction in both groups ( − 3·28 kg and − 2·67 kg in NOPE–EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE–EGCG treatment improved insulin resistance (P < 0·001), the sensation feelings of fullness (P < 0·05), depressive symptoms (P < 0·004) and severity of binge eating (P < 0·0001). Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85mg NOPE and 50mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6% in the NOPE-EGCG group and 27% in the placebo group (P<0.001). The treatment induced a significant weight reduction in both groups (-3.28kg and -2.67kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P<0.001), the sensation feelings of fullness (P<0.05), depressive symptoms (P<0.004) and severity of binge eating (P<0.0001). Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0.001). The treatment induced a significant weight reduction in both groups ( - 3.28 kg and - 2.67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0.001), the sensation feelings of fullness (P < 0.05), depressive symptoms (P < 0.004) and severity of binge eating (P < 0.0001). Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0·001). The treatment induced a significant weight reduction in both groups ( - 3·28 kg and - 2·67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0·001), the sensation feelings of fullness (P < 0·05), depressive symptoms (P < 0·004) and severity of binge eating (P < 0·0001). [PUBLICATION ABSTRACT] |
| Author | Solerte, Sebastiano Bruno Cazzola, Roberta Klersy, Catherine Opizzi, Annalisa Trotti, Rosita Rondanelli, Mariangela |
| Author_xml | – sequence: 1 givenname: Mariangela surname: Rondanelli fullname: Rondanelli, Mariangela email: serv.nutrizione@asppavia.it organization: 1Section of Human Nutrition and Dietetics, Department of Applied Health Sciences, Faculty of Medicine, University of Pavia, Pavia, Italy – sequence: 2 givenname: Annalisa surname: Opizzi fullname: Opizzi, Annalisa organization: 1Section of Human Nutrition and Dietetics, Department of Applied Health Sciences, Faculty of Medicine, University of Pavia, Pavia, Italy – sequence: 3 givenname: Sebastiano Bruno surname: Solerte fullname: Solerte, Sebastiano Bruno organization: 3Department of Internal Medicine, Geriatrics and Gerontologic Clinic, University of Pavia, ‘Istituto Santa Margherita’, Pavia, Italy – sequence: 4 givenname: Rosita surname: Trotti fullname: Trotti, Rosita organization: 4Laboratory of Biochemical Chemistry, Neurological Institute ‘C. Mondino’, IRCCS, Pavia, Italy – sequence: 5 givenname: Catherine surname: Klersy fullname: Klersy, Catherine organization: 5Service of Biometry and Clinical Epidemiology, Fondazione IRCCS ‘Policlinico San Matteo’, Pavia, Italy – sequence: 6 givenname: Roberta surname: Cazzola fullname: Cazzola, Roberta organization: 6Department of Preclinical Sciences ‘LITA Vialba’, Faculty of Medicine, University of Milan, Milan, Italy |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21200816$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18590587$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkttu1DAQhiNURA_wANyAVQkEFwE7B9vLXVVBQXRBVanEXeQ4k40XJw62l7I8Iw_FpLsUqQh6ZY_8zcw_nn8_2RncAEnykNEXjDLx8pxSKhgrSippVlAq7yR7rBBlmnGe7SR703M6ve8m-yEsMZSMzu4lu0yWM1pKsZf8PGp6M5gQvYrGDcS1RJHGQFR-TcJqHC30METy7EPqLKxtOnYujB3CzdpC7NTgrMIKQNTQEBjNQlnrtIqgOzOkeTrFGJHW-X5l1XMCAyZpCES7frRmupNLE7urrsQMpANlY7cm7hv4SzCLLqKQegk6hlcozmMj15sf0GCFIXpnLV6jN8reT-62ygZ4sD0Pkos3rz8dv01PP568Oz46TXXJRUxVLXMJoqYsr6VuqajrogXeNLUWXNcFBaXzpi1nPGtUqfKcF7KRWT2TnDeizvOD5Omm7ujd1xWEWPUmaMBBB3CrUHEuWV5m9Faw4JmkSN8KZiyjUhQMwcMb4NKt_IDTIpPLvOSZQOjRFlrVPTTV6E2P-6x-rx2BJ1tABa1si3-qTbjmpm5oFY6c2HDauxA8tJU28coo6BdjK0aryYjVX0bETHYj81rEf3LSTQ7aEb5fJyj_peIiF2XFT86q-Xx-Vh5_fl9NUzze8K1ylVp4nODiPMOtUpSe4fqQyLcqVF970yzgz3f9W8cv5IAKtw |
| CODEN | BJNUAV |
| CitedBy_id | crossref_primary_10_1177_0897190010362104 crossref_primary_10_3945_ajcn_111_032573 crossref_primary_10_1016_j_physbeh_2015_11_032 crossref_primary_10_1111_obr_12914 crossref_primary_10_1080_10408398_2014_889653 crossref_primary_10_1111_obr_12854 crossref_primary_10_3389_fendo_2022_917692 crossref_primary_10_1111_1440_1681_13238 crossref_primary_10_1111_obr_12853 crossref_primary_10_1186_1476_511X_11_127 crossref_primary_10_1007_s13596_024_00770_1 crossref_primary_10_1080_07315724_2017_1333470 crossref_primary_10_1080_10408398_2013_871221 crossref_primary_10_1007_BF03344776 crossref_primary_10_1080_07315724_2013_767667 crossref_primary_10_1007_s12020_012_9863_0 crossref_primary_10_1016_j_appet_2018_05_129 crossref_primary_10_3390_molecules23050999 crossref_primary_10_1089_jmf_2019_0145 crossref_primary_10_3390_nu11092238 crossref_primary_10_1002_oby_23110 crossref_primary_10_1038_s41366_021_00839_w crossref_primary_10_3390_life14101342 crossref_primary_10_3389_fnut_2022_940064 crossref_primary_10_1016_j_phymed_2009_10_001 crossref_primary_10_3390_antiox10111644 crossref_primary_10_1038_s41386_020_0722_z crossref_primary_10_1002_jcp_27913 crossref_primary_10_1016_j_neubiorev_2023_105225 |
| Cites_doi | 10.1016/0163-7827(90)90004-5 10.1113/jphysiol.2004.081844 10.1007/BF03327740 10.1002/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A 10.1016/S0140-6736(77)90494-9 10.1210/jcem.85.7.6661 10.1046/j.1365-2265.2003.01836.x 10.1093/ajcn/40.4.808 10.1080/07315724.1992.12098245 10.1016/j.ejphar.2005.12.024 10.1037/0278-6133.12.5.342 10.1006/abbi.1993.1110 10.1002/j.1550-8528.1995.tb00466.x 10.1001/jama.295.7.761 10.1007/s002130050953 10.1016/j.cmet.2006.02.004 10.1186/1479-5868-1-12 10.1016/S1098-3597(99)90002-9 10.1523/JNEUROSCI.23-12-04815.2003 10.1038/382677a0 10.1016/0306-4603(82)90024-7 10.1093/clinchem/18.6.499 10.1136/bmj.322.7299.1406 10.1093/ajcn/70.6.1040 10.1002/(SICI)1098-1128(199707)17:4<327::AID-MED2>3.0.CO;2-Y 10.1038/sj.ijo.0803008 10.1016/j.brainres.2006.06.062 10.1001/jama.284.3.291 10.1093/ajcn/81.1.243S 10.1210/endo.141.3.7368 10.1038/sj.ijo.0802727 10.1080/10408690390826464 10.1038/nature01921 10.1001/archinte.161.13.1581 10.2337/diacare.19.10.1138 |
| ContentType | Journal Article |
| Copyright | Copyright © The Authors 2008 2009 INIST-CNRS |
| Copyright_xml | – notice: Copyright © The Authors 2008 – notice: 2009 INIST-CNRS |
| DBID | FBQ BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QP 7RV 7T5 7X2 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. KB0 M0K M0S M1P M2O MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7TS 7S9 L.6 7X8 |
| DOI | 10.1017/S0007114508024008 |
| DatabaseName | AGRIS Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Immunology Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Agricultural Science Database ProQuest Health & Medical Collection Medical Database ProQuest Research Library Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic Physical Education Index AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition Agricultural Science Collection British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) Physical Education Index AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | AGRICOLA CrossRef MEDLINE - Academic Physical Education Index MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Diet & Clinical Nutrition |
| DocumentTitleAlternate | Compliance with diet and oral supplementation M. Rondanelli et al. |
| EISSN | 1475-2662 |
| EndPage | 464 |
| ExternalDocumentID | 1625405111 18590587 21200816 10_1017_S0007114508024008 ark_67375_6GQ_MMMQ5CXK_7 US201301632596 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | --- -E. -~X .FH 09C 09E 0E1 0R~ 23N 2WC 3EH 3V. 4.4 5GY 5RE 5VS 6J9 6PF 74X 74Y 7RV 7X2 7X7 7~V 88E 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 9M5 AAAZR AABES AABWE AACJH AAEED AAFWJ AAGFV AAIKC AAKTX AAMNQ AAMNW AARAB AASVR AATID AAUIS AAUKB AAWTL AAZAQ ABBJB ABBXD ABFBI ABGDZ ABJNI ABKKG ABKMT ABMWE ABMYL ABQTM ABROB ABUWG ABWCF ABZCX ABZUI ACBEK ACBMC ACCHT ACGFS ACIMK ACPRK ACQFJ ACREK ACUIJ ACUYZ ACWGA ACYZP ACZBM ACZUX ACZWT ADAZD ADBBV ADDNB ADFEC ADFRT ADGEJ ADKIL ADOCW ADVJH AEBAK AEHGV AEMTW AENEX AENGE AEPLO AEYHU AEYYC AFFNX AFFUJ AFKQG AFKRA AFLOS AFLVW AFOSN AFRAH AFRIC AFUTZ AGABE AGJUD AGOOT AHIPN AHLTW AHMBA AHQXX AHRGI AIGNW AIHIV AIOIP AISIE AJ7 AJCYY AJPFC AJQAS ALMA_UNASSIGNED_HOLDINGS ALWZO AN0 ANPSP AQJOH ATCPS ATUCA AUXHV AZGZS AZQEC BAWUL BBLKV BENPR BHPHI BKEYQ BLZWO BNQBC BPHCQ BQFHP BRIRG BVXVI C0O C1A CAG CBIIA CCPQU CCQAD CFAFE CHEAL CJCSC COF CS3 DIK DOHLZ DU5 DWQXO E3Z EBS EJD EX3 F5P FYUFA GNUQQ GUQSH HCIFZ HG- HH5 HMCUK HZ~ I.6 IH6 IOEEP IOO IS6 I~P J36 J38 J3A JHPGK JKPOH JQKCU JVRFK KCGVB KFECR L7B L98 LW7 M-V M0K M1P M2O M7~ NAPCQ NIKVX O9- OK1 OVD P6G PCD PQQKQ PROAC PSQYO Q2X RAMDC RCA RIG ROL RR0 S6- S6U SAAAG SJN SY4 T9M TEORI TR2 UCJ UKHRP UT1 UU6 WFFJZ WH7 WOW WQ3 WXU WYP Y6R ZA5 ZMEZD ZYDXJ ~KM -1D -1F -2P -2V -~6 -~N .55 .GJ 354 3O- 53G 6~7 AAHBH AANRG AATMM AAYJJ ABBZL ABHFL ABVFV ABVKB ABVZP ABXAU ACDLN ACEJA ACETC ACOZI ACRPL ADNMO ADOVH ADOVT AEBPU AEMFK AENCP AEUYN AFZFC AGKLZ AGLWM AI. AKZCZ ALEEW ANOYL ARABE ARZZG AYIQA BCGOX BESQT BGHMG BJBOZ BMAJL CCUQV CDIZJ CFBFF CGQII EGQIC FBQ HST I.7 I.9 KAFGG LHUNA M8. NMFBF NZEOI OHT PHGZT UAP VH1 X7M ZCG ZDLDU ZGI ZJOSE ZXP ~V1 ABXHF AGQPQ AKMAY BSCLL PHGZM PJZUB PPXIY PUEGO AAYXX CITATION AAKNA IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI Q9U 7TS 7S9 L.6 7X8 |
| ID | FETCH-LOGICAL-c567t-ab838e7b013b8cf07bb4fe6ddbc76cb40eac3df5962da5a33648d82b9866d7b33 |
| IEDL.DBID | 7X7 |
| ISSN | 0007-1145 1475-2662 |
| IngestDate | Thu Aug 07 14:38:41 EDT 2025 Mon Jul 21 11:28:10 EDT 2025 Fri Jul 11 02:17:41 EDT 2025 Sat Aug 23 13:05:13 EDT 2025 Wed Feb 19 01:43:17 EST 2025 Mon Jul 21 09:17:11 EDT 2025 Tue Jul 01 03:49:58 EDT 2025 Thu Apr 24 23:06:27 EDT 2025 Sun Aug 31 06:50:54 EDT 2025 Thu Apr 03 09:46:52 EDT 2025 Wed Mar 13 05:52:23 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Appetite Insulin resistance N-oleyl-phosphatidylethanolamine Dietary adherence Epigallocatechin-3-gallate Endocrinopathy Phosphatidylethanolamine Healthy subject Compliance Metabolic diseases Adhesion Feeding Overweight Dietary adherence: Insulin resistance: Appetite: N-oleyl-phosphatidylethanolamine: Epigallocatechin-3-gallate Target tissue resistance Vertebrata Mammalia Diet |
| Language | English |
| License | https://www.cambridge.org/core/terms CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c567t-ab838e7b013b8cf07bb4fe6ddbc76cb40eac3df5962da5a33648d82b9866d7b33 |
| Notes | http://dx.doi.org/10.1017/S0007114508024008 PII:S0007114508024008 istex:8C25AF2C135EDFB21BDE505DDC497020B0FBE4EA Abbreviations: EGCG, epigallocatechin-3-gallate; HOMA, homeostasis model assessment; NOE, N-oleyl-ethanolamide; NOPE, N-oleyl-phosphatidylethanolamine; QUICKI, quantitative insulin sensitivity check index ArticleID:02400 ark:/67375/6GQ-MMMQ5CXK-7 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/AC58828057125C798A40DCF1DAB95B95/S0007114508024008a.pdf/div-class-title-administration-of-a-dietary-supplement-span-class-italic-n-span-oleyl-phosphatidylethanolamine-and-epigallocatechin-3-gallate-formula-enhances-compliance-with-diet-in-healthy-overweight-subjects-a-randomized-controlled-trial-div.pdf |
| PMID | 18590587 |
| PQID | 213835627 |
| PQPubID | 5629 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_66813520 proquest_miscellaneous_46280668 proquest_miscellaneous_21208741 proquest_journals_213835627 pubmed_primary_18590587 pascalfrancis_primary_21200816 crossref_citationtrail_10_1017_S0007114508024008 crossref_primary_10_1017_S0007114508024008 istex_primary_ark_67375_6GQ_MMMQ5CXK_7 fao_agris_US201301632596 cambridge_journals_10_1017_S0007114508024008 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-Feb |
| PublicationDateYYYYMMDD | 2009-02-01 |
| PublicationDate_xml | – month: 02 year: 2009 text: 2009-Feb |
| PublicationDecade | 2000 |
| PublicationPlace | Cambridge, UK |
| PublicationPlace_xml | – name: Cambridge, UK – name: Cambridge – name: England |
| PublicationTitle | British journal of nutrition |
| PublicationTitleAlternate | Br J Nutr |
| PublicationYear | 2009 |
| Publisher | Cambridge University Press |
| Publisher_xml | – name: Cambridge University Press |
| References | S0007114508024008_ref29 S0007114508024008_ref27 American Psychiatric Association (S0007114508024008_ref20) 1994 Katz (S0007114508024008_ref28) 2000; 85 S0007114508024008_ref35 S0007114508024008_ref13 S0007114508024008_ref33 S0007114508024008_ref11 S0007114508024008_ref10 S0007114508024008_ref32 MacLachlan (S0007114508024008_ref37) 1991; 15 S0007114508024008_ref30 Broccali (S0007114508024008_ref19) 2005; 164 Friedewald (S0007114508024008_ref26) 1972; 18 Lamberg (S0007114508024008_ref34) 2000; 284 S0007114508024008_ref18 S0007114508024008_ref39 S0007114508024008_ref17 S0007114508024008_ref16 S0007114508024008_ref38 S0007114508024008_ref15 S0007114508024008_ref14 Wadden (S0007114508024008_ref36) 2002 S0007114508024008_ref4 S0007114508024008_ref3 Steer (S0007114508024008_ref31) 1999; 55 S0007114508024008_ref2 Goldstein (S0007114508024008_ref24) 1992; 16 S0007114508024008_ref1 S0007114508024008_ref23 S0007114508024008_ref22 S0007114508024008_ref9 S0007114508024008_ref42 S0007114508024008_ref8 S0007114508024008_ref41 Chen (S0007114508024008_ref12) 1997; 25 S0007114508024008_ref7 S0007114508024008_ref6 Kushner (S0007114508024008_ref25) 1992; 11 (S0007114508024008_ref21) 1985 S0007114508024008_ref40 S0007114508024008_ref5 |
| References_xml | – ident: S0007114508024008_ref13 doi: 10.1016/0163-7827(90)90004-5 – ident: S0007114508024008_ref32 doi: 10.1113/jphysiol.2004.081844 – ident: S0007114508024008_ref4 doi: 10.1007/BF03327740 – volume: 55 start-page: 117 year: 1999 ident: S0007114508024008_ref31 article-title: Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients publication-title: J Clin Psychol doi: 10.1002/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A – ident: S0007114508024008_ref29 doi: 10.1016/S0140-6736(77)90494-9 – volume: 85 start-page: 2402 year: 2000 ident: S0007114508024008_ref28 article-title: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.85.7.6661 – ident: S0007114508024008_ref41 doi: 10.1046/j.1365-2265.2003.01836.x – ident: S0007114508024008_ref22 doi: 10.1093/ajcn/40.4.808 – volume: 11 start-page: 199 year: 1992 ident: S0007114508024008_ref25 article-title: Bioelectrical impedance analysis: a review of principles and applications publication-title: J Am Coll Nutr doi: 10.1080/07315724.1992.12098245 – ident: S0007114508024008_ref38 doi: 10.1016/j.ejphar.2005.12.024 – ident: S0007114508024008_ref35 doi: 10.1037/0278-6133.12.5.342 – ident: S0007114508024008_ref14 doi: 10.1006/abbi.1993.1110 – ident: S0007114508024008_ref23 doi: 10.1002/j.1550-8528.1995.tb00466.x – volume: 15 start-page: 27 year: 1991 ident: S0007114508024008_ref37 article-title: Psychological aspects of dietary weight loss and medication with the a typical beta agonist BRL 26830A in obese subjects publication-title: Int J Obes – ident: S0007114508024008_ref42 doi: 10.1001/jama.295.7.761 – ident: S0007114508024008_ref16 doi: 10.1007/s002130050953 – ident: S0007114508024008_ref18 doi: 10.1016/j.cmet.2006.02.004 – ident: S0007114508024008_ref6 doi: 10.1186/1479-5868-1-12 – ident: S0007114508024008_ref33 doi: 10.1016/S1098-3597(99)90002-9 – ident: S0007114508024008_ref40 doi: 10.1523/JNEUROSCI.23-12-04815.2003 – ident: S0007114508024008_ref15 doi: 10.1038/382677a0 – ident: S0007114508024008_ref30 doi: 10.1016/0306-4603(82)90024-7 – volume: 164 start-page: 101 year: 2005 ident: S0007114508024008_ref19 article-title: N-oleoyl-phosphatidylethanolamine reduces food intake and body weight of dietary obese rats ameliorating their antioxidant status publication-title: Gazz Med Ital Arch Sci Med – start-page: 144 volume-title: Handbook of Obesity Treatment year: 2002 ident: S0007114508024008_ref36 – volume: 16 start-page: 397 year: 1992 ident: S0007114508024008_ref24 article-title: Beneficial health effects of modest weight loss publication-title: Int J Obes Relat Metab Disord – volume: 18 start-page: 499 year: 1972 ident: S0007114508024008_ref26 article-title: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge publication-title: Clin Chem doi: 10.1093/clinchem/18.6.499 – ident: S0007114508024008_ref3 doi: 10.1136/bmj.322.7299.1406 – ident: S0007114508024008_ref10 doi: 10.1093/ajcn/70.6.1040 – ident: S0007114508024008_ref8 doi: 10.1002/(SICI)1098-1128(199707)17:4<327::AID-MED2>3.0.CO;2-Y – ident: S0007114508024008_ref2 doi: 10.1038/sj.ijo.0803008 – ident: S0007114508024008_ref39 doi: 10.1016/j.brainres.2006.06.062 – volume: 284 start-page: 291 year: 2000 ident: S0007114508024008_ref34 article-title: Psychiatric help may shrink some waistlines publication-title: JAMA doi: 10.1001/jama.284.3.291 – ident: S0007114508024008_ref11 doi: 10.1093/ajcn/81.1.243S – volume-title: Energy and Protein Requirements year: 1985 ident: S0007114508024008_ref21 – ident: S0007114508024008_ref9 doi: 10.1210/endo.141.3.7368 – volume: 25 start-page: 1045 year: 1997 ident: S0007114508024008_ref12 article-title: Absorption, distribution, elimination of tea polyphenols in rats publication-title: Drug Metab Dispos – ident: S0007114508024008_ref5 doi: 10.1038/sj.ijo.0802727 – ident: S0007114508024008_ref7 doi: 10.1080/10408690390826464 – start-page: 317 volume-title: Diagnostic and Statistical Manual of Mental Disorders year: 1994 ident: S0007114508024008_ref20 – ident: S0007114508024008_ref17 doi: 10.1038/nature01921 – ident: S0007114508024008_ref1 doi: 10.1001/archinte.161.13.1581 – ident: S0007114508024008_ref27 doi: 10.2337/diacare.19.10.1138 |
| SSID | ssj0008109 |
| Score | 2.0877664 |
| Snippet | Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit... Many studies have found that N -oleyl-ethanolamine (NOE), a metabolite of N -oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG)... |
| SourceID | proquest pubmed pascalfrancis crossref istex fao cambridge |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 457 |
| SubjectTerms | administration & dosage Adolescent Adult analogs & derivatives analysis Appetite Appetite Depressants Appetite Depressants - administration & dosage binging Biological and medical sciences Biomarkers Biomarkers - blood blood Blood Glucose Blood Glucose - analysis Body Composition Catechin Catechin - administration & dosage Catechin - analogs & derivatives Depression Diet diet therapy Diet, Reducing Dietary adherence Dietary Supplements Double-Blind Method Eating Eating behavior epigallocatechin Epigallocatechin-3-gallate ethanolamine Feeding. Feeding behavior Female Females food intake Fundamental and applied biological sciences. Psychology human nutrition Humans Insulin Insulin - blood Insulin resistance low calorie diet Male Males men metabolism Metabolites Middle Aged N-oleyl-phosphatidylethanolamine Nutrition nutritional intervention Obesity overweight Overweight - blood Overweight - diet therapy Patient Compliance Phosphatidylethanolamines Phosphatidylethanolamines - administration & dosage randomized clinical trials Satiation Statistics, Nonparametric Vertebrates: anatomy and physiology, studies on body, several organs or systems Weight control Weight Loss women |
| Title | Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial |
| URI | https://www.cambridge.org/core/product/identifier/S0007114508024008/type/journal_article https://api.istex.fr/ark:/67375/6GQ-MMMQ5CXK-7/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/18590587 https://www.proquest.com/docview/213835627 https://www.proquest.com/docview/21208741 https://www.proquest.com/docview/46280668 https://www.proquest.com/docview/66813520 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELbY3QsXxHvDQvEBrQBhkaftckFQdlmBWrFApd4iO3ZoRUhK00qU38iPYsZJs1SovURJY7uOPZ4Zz3yeIeRJDFIOeJ5lsHQsizXPmLQ8YnHk-0pZENkK7R3DEb8Yxx8myaTF5tQtrHLDEx2jNlWGNvKXYQB7KRDW4vX8J8OkUehcbTNoHJAjjFyGRC0m3X4LhF2L8MA4iEGcbJyaLmI0ylb4DY-aAhnLf0MrbImog1xVoLjimP9C4KSqYezyJunFbq3USafzm-RGq1bSNw0d3CLXbHmbeO9mdklPaRv7s6CjTej9O-TPdtRcWuVUUQPl1WJNa0z16eyG9OmIVcA3CjafVvV8CoXNGqZ6qkrYE0MLlqrSUDufOQ8-wqsQnMkihs_wRFEpXhXqGbXlFCmspg2KHe8pWoHdv9JZSZsjmWtaOaw2Gg2gIxrtRPUr6BwMhql-zH5bQ1t8fQG3LuvIXTI-P_s6uGBtZgeWJVwsmdIyklagDVbLLPeF1nFuuTE6EzzTsQ_iIDI5ZgYyKlFRxGNpZKj7knMjdBTdI4dlVdpjQn0b5FrlfUxnHofa13k_yMIstjLMQfRGHnnRTWzars86bbBtIv2PDjzib-Y-zdoo6Ziso9hX5XlXZd6ECNlX-BgIKlXfgIWn4y8hOo5BJYZNKPfIqaOyrhG1-I6wO5Gk_P1lOhwOL5PB5GMqPNLbIsOuAqghSPXQ0smGLq8-uVtAHnncvQVegg4iVdpqVbv6ElTM3SXwJDMoqXJ3CXgZgFLve-R-syCuxkQmfT-R4sHe3p2Q643DDhFDD8nhcrGyj0DvW-qeW91wlYOgR47eno0-ff4LvCVWkA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGeIAXxH1hsPkBJkBY5B4XCSHUMTq6VppYpb5lduzQipKUphWU_8Q_4UdxjnMpFWrf9pY0tuPmXH38-RxCnvpg5UDnaQaio5kvw4RxHXrM92xbCA0mW2C8o9cPOwP_0zAY7pDf9VkYhFXWOtEoapUnGCN_7TqwlgJjHb2bfmdYNAo3V-sKGiVXdPXyB6zYirenx0DeZ6578uGi3WFVUQGWBGE0Z0Jyj-sIw3-SJ6kdSemnOlRKJlGYSN8GTeSpFIvSKBEIzwt9rrgrWzwMVSQx_gka_7rvgWTiwfT2ClHCnQpRgnkXHT-oN1FNhmq05fAbHm0FseH_pnJYM4nXUpGDo4w0_olATVEArdKyyMZmL9hYw5Pb5FblxtL3Jd_dITs6u0us47Ge0yNa5Rqd0H6d6v8e-bOepZfmKRVUQXsxW9ICS4uaOCV93mc56KkJm47yYjqCxmoJrDUSGazBYQRNRaaono4NYgDhXAgGZR7De7ij6IQvJuIF1dkIObqgJWoerylGnc1b6Tij5RHQJc0NNhyDFDARiXGp4g1MDj6Gyr-Nf2lFKzz_BC5NlZP7ZHAlRH9AdrM803uE2tpJpUhbWD7dd6Ut05aTuImvuZuCqfcs8qohbFzpgyIusXRR_B8fWMSuaR8nVVZ2LA4y2dblZdNlWqYk2dZ4DxgqFl_AZMSDzy5uVIMLDove0CJHhsuaQcTsK8L8oiAOP57HvV7vPGgPu3FkkYM1Nmw6gNuDXA8j7dd8ufrLjcBa5LB5CroLN6REpvNFYfpzcGk3t8CT0-AU880t4KEDiwjbIg9LgVh9Ex607IBHj7bO7pDc6Fz0zuKz0353n9wsNwsRrfSY7M5nC_0EfM65PDCSTsnlVauWv90nkpI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkBAviPvCYPMDTICwlrtdJIRQS9korZigUt8yO3ZoRUlK0wrKP-M_8KM4J7dSofVtb0ljO27O1cefzyHksQ9WDnSeYSA6hvkqjJkwocd8z7alNGCyJcY7-oPwZOi_HwWjHfK7PguDsMpaJxaKWmcxxsiPXQfWUmCs-XFSoSI-drqvZ98ZFpDCjda6mkbJIT2z-gGrt_zVaQdI_cR1u28_t09YVWCAxUHIF0wq4QnDMRSoRJzYXCk_MaHWKuZhrHwbtJKnEyxQo2UgPS_0hRauaokw1FxhLBS0_1XucYEiJtprdIlwKnQJ5mB0_KDeUC2yVaNdh9_wmCuIkPg3rcOGebySyAycZqT3TwRtyhzolpQFNy72iAvL2L1JblQuLX1T8uAtsmPS28TqTMyCHtEq7-iUDuq0_3fIn82MvTRLqKQa2sv5iuZYZrSIWdKnA5aBzpqy2TjLZ2NorFfAZmOZwnocRjBUppqa2aRADyC0C4GhzGN4D3cUHfLlVD6jJh0jd-e0RNDjNcUIdPFWOklpeRx0RbMCJ44BC5iIwhhV_hImBx9DZ98mv4ymFbZ_CpdFxZO7ZHgpRL9HdtMsNXuE2sZJlExaWErdd5WtkpYTu7FvhJuA2fcs8qIhbFTphjwqcXU8-o8PLGLXtI_iKkM7FgqZbuvyvOkyK9OTbGu8BwwVyS9gPqLhJxc3rcEdhwVwaJGjgsuaQeT8K0L-eBCF786ifr9_FrRHvYhb5GCDDZsO4AIh18NI-zVfrv9yI7wWOWyegh7DzSmZmmyZF_0FuLcXt8BT1OAgi4tbwEMHFhS2Re6XArH-JiJo2YHgD7bO7pBcA6USfTgd9PbJ9XLfEIFLD8nuYr40j8D9XKiDQtApOb9szfIX4CyWyA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Administration+of+a+dietary+supplement+%28N-oleyl-phosphatidylethanolamine+and+epigallocatechin-3-gallate+formula%29+enhances+compliance+with+diet+in+healthy+overweight+subjects%3A+a+randomized+controlled+trial&rft.jtitle=British+journal+of+nutrition&rft.au=Rondanelli%2C+Mariangela&rft.au=Opizzi%2C+Annalisa&rft.au=Solerte%2C+Sebastiano+Bruno&rft.au=Trotti%2C+Rosita&rft.date=2009-02-01&rft.pub=Cambridge+University+Press&rft.issn=0007-1145&rft.eissn=1475-2662&rft.volume=101&rft.issue=3&rft.spage=457&rft_id=info:doi/10.1017%2FS0007114508024008&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=1625405111 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1145&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1145&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1145&client=summon |